Author

Tao Fan

Observed name: Fan, Tao

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences

OpenAlex ID: A5005280490

Regulatory T cells in immune checkpoint blockade antitumor therapy

2024 · An Zhang, Tao Fan, et al. · Molecular Cancer · 151

Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9

2025 · Tao Fan, Chu Xiao, et al. · Respiratory Research · 5

BATF reprograms the tumor immune status

2023 · Tao Fan, Chu Xiao, et al. · Med · 2

Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience

2026 · Riddhi A. Babel, Stephen V. Liu, et al. · Future Oncology

Impact on overall survival after adjusting for treatment crossover in first-line metastatic NSCLC trials for pembrolizumab plus chemotherapy.

2026 · Ying Zhang, Riddhi Babel, et al. · Journal of Clinical Oncology

Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison

2026 · Danmeng Huang, Ying Zhang, et al. · Journal of Medical Economics

Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison

2026 · Huang, Danmeng, Zhang, Ying, et al. · Figshare

Works count: 7

Citation count: 157

H-index: 2

I10-index: 1